Corporate Overview
Thallion Pharmaceuticals Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology, with a current emphasis on developing a treatment for Shigatoxin-producing E. coli (STEC) bacterial infections.
The Company's leading product candidate is Shigamabs®, a dual antibody product for the treatment of Shigatoxin-producing E. coli (STEC) bacterial infections. Thallion has completed four Phase I clinical trials evaluating the safety of Shigamabs®, which demonstrated that the antibodies are safe and well tolerated when administered both individually and in combination. In February, 2010, Thallion signed a definitive development and license agreement with Laboratoire français du Fractionnement et des Biotechnologies (LFB) for payments of up to €95 million, including a €1.5 million upfront payment. LFB received commercial rights to Shigamabs® for Europe, South America and other territories of strategic interest to LFB, including Russia, Turkey, China, South Korea and Northern African countries, while Thallion retained the rights for North America and the rest of world. The Company initiated a Phase II clinical trial in South America in November 2010 to evaluate Shigamabs® as a treatment for STEC infections. The study will comprise up to 17 clinical sites in Argentina, Chile and Peru.
Thallion also owns a proprietary technology platform named DECIPHER®, a genomics-based discovery platform for identifying novel secondary metabolites from non-pathogenic microorganisms. Derived from DECIPHER®, Thallion's product portfolio also includes TLN-4601, a novel small molecule with potential efficacy in multiple oncology applications, including both solid and liquid tumors. The Company had progressed the compound into Phase II development and it is currently evaluating its options to monetize the TLN-4601 program, including the possibility of out-licensing the program assets.
Thallion was formed in March 2007 as part of an Arrangement under Section 192 of the Canada Business Corporations Act ("CBCA"), amalgamating Ecopia Biosciences Inc. and Caprion Pharmaceuticals Inc.
Thallion also owns approximately a 16% stake in Caprion Proteomics Inc. formed by Great Point Partners, LLC of Greenwich, Connecticut following Thallion's divestiture of its CellCarta proteomics technology platform on July 10, 2007.
The head office and registered office and principal place of business of Thallion is located at 1375 TransCanada Highway, Suite 200, Dorval, Québec, H9P 2W8.
Thallion's shares are listed and traded on the Toronto Stock Exchange (TSX) under the symbol TLN.